Optimer Pharmaceuticals, Inc. Halts Study After Pruvel, an Antibiotic for Traveler’s Diarrhea, Linked to Rash

Nov 10 (Reuters) - Optimer Pharmaceuticals Inc (OPTR.O) said it would terminate a research study of its infectious diarrhea drug candidate, citing higher-than-expected incidences of skin rashes, potentially delaying its marketing application.